Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.36 |
| ▸ | CDK9 | P50750 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436613 | 0.81 | SIGMAR1 (0.42) | MEN1KMT2ASIGMAR1CCNT1CDK9 | |
| SCHEMBL3554023 | 0.79 | DRD2 (0.43) | SIGMAR1DRD2KDM4EHTR1ADRD4 | |
| SCHEMBL3551951 | 0.74 | ATM (0.41) | MEN1KMT2ASIGMAR1CCNT1CDK9 | |
| SCHEMBL3552452 | 0.69 | MEN1 (0.41) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL3466789 | 0.68 | PDK4 (0.58) | CCNT1CDK9 | |
| SCHEMBL30852130 | 0.68 | PRMT1 (0.50) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL27313226 | 0.68 | SIGMAR1 (0.35) | MEN1KMT2ASIGMAR1KDM4EMAPT | |
| SCHEMBL3436711 | 0.66 | CCNT1 (0.43) | SIGMAR1CCNT1CDK9KDM4EMAPT | |
| SCHEMBL28971538 | 0.65 | ALDH1A1 (0.46) | MEN1KMT2AKDM4EMAPTLMNA | |
| SCHEMBL3436712 | 0.65 | CDK9 (0.42) | SIGMAR1CCNT1CDK9KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | MEN1 4778/4885KMT2A 1707/4885SIGMAR1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.